Antonio Atanes

TL;DR: In this article, the authors conducted a multicenter study of patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and anti-tumor necrosis factor (anti-TNF) agents.

TL;DR: Anti-TNF-α therapy is effective and relatively safe in refractory BD uveitis and the best-corrected visual acuity and the suppression load also showed significant improvement.

TL;DR: TCZ yielded rapid and maintained improvement in all ocular parameters of the patients, with complete remission in eight of them, but this was not the case for the extraocular manifestations, since TCZ was only effective in three of them.

TL;DR: Macular thickness is reduced following administration of tocilizumab (TCZ) in refractory uveitis-related CME, a statistically significant improvement in macular thickness compared to baseline.

TL;DR: The results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis and rapid and progressive improvement of intraocular inflammation parameters.